# US 2023/0074330 A1 · Pde5 compositions and methods for immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0074330 A1
- Document ID: US20230074330A1
- Status: Published application
- Kind: A1
- Application number: 17/649,592
- Filed: 2022-02-01
- Published: 2023-03-09
- Earliest claimed: 2017-06-12
- Assignees: Obsidian Therapeutics, Inc.
- Applicants: Obsidian Therapeutics, Inc.
- Inventors: Vipin Suri; Byron Delabarre; Michael N. Gladstone; Celeste Richardson; Brian Dolinski; Abhishek Kulkarni; Mara Christine Inniss; Dexue Sun; Dan Jun Li; Grace Y. Olinger; Scott Francis Heller
- Web page: https://patentgrep.com/patent/US20230074330A1

## CPC

- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 38/2086: {IL-13 to IL-16}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4211: {CD19 or B4}
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 14/5443: {IL-15}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 14/7155: {for interleukins [IL]}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- C12N 9/16: acting on ester bonds (3.1)
- C12Y 301/04035: 3',5'-Cyclic-GMP phosphodiesterase (3.1.4.35)
- A61K 2039/505: {comprising antibodies}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C07K 2317/53: Hinge
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/95: containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to compositions and methods for the regulated and controlled expression of proteins. Methods for inducing anti-cancer immune responses in a subject are also provided.

## Claims

### Claim at position 1

1-51. (canceled)

### Claim 52

A composition comprising an effector module, said effector module comprising a stimulus response element (SRE) and at least one payload which is operably linked to said SRE, wherein the SRE comprises a destabilizing domain (DD), wherein the DD comprises the catalytic domain of a human cGMP-specific 3′,5′-cyclic phosphodiesterase (hPDE5), wherein the DD comprises SEQ ID NO: 3, and wherein the DD further comprises a mutation in the amino acid at the position corresponding to amino acid 732 (R732) of SEQ ID NO: 1.

### Claim 53 (depends on 52)

The composition of claim 52, wherein the mutation in the amino acid at position 732 (R732) is selected from the group consisting of R732L, R732A, R732G, R732V, R732I, R732P, R732F, R732W, R732Y, R732H, R732S, R732T, R732D, R732E, R732Q, R732N, R732M, R732C, and R732K.

### Claim 54 (depends on 53)

The composition of claim 53, wherein the mutation in the amino acid at position R732 is R732L.

### Claim 55 (depends on 52)

The composition of claim 52, wherein the DD further comprises a mutation in the amino acid at the position corresponding to amino acid 764 (D764) of SEQ ID NO: 1, wherein the mutation at D764 is selected from the group consisting of D764N and D764A.

### Claim 56 (depends on 52)

The composition of claim 52, wherein the DD further comprises a mutation in the amino acid at the position corresponding to amino acid 612 (Y612) of SEQ ID NO: 1, wherein the mutation at Y612 is selected from the group consisting of Y612A, Y612F, and Y612W.

### Claim 57 (depends on 52)

The composition of claim 52, wherein the DD further comprises an F736A mutation in the amino acid at the position corresponding to amino acid 736 (F736) of SEQ ID NO: 1.

### Claim 58 (depends on 52)

The composition of claim 52, wherein the DD further comprises an H653A mutation in the amino acid at the position corresponding to amino acid 653 (H653) of SEQ ID NO: 1.

### Claim 59 (depends on 52)

The composition of claim 52, wherein the payload is an immunotherapeutic agent.

### Claim 60 (depends on 59)

The composition of claim 59, wherein the immunotherapeutic agent is selected from a chimeric antigen receptor (CAR), a cytokine, a cytokine-cytokine receptor fusion polypeptide.

### Claim 61 (depends on 60)

The composition of claim 60, wherein the immunotherapeutic agent is a chimeric antigen receptor (CAR) that comprises:
(a) an extracellular target moiety;
(b) a transmembrane domain;
(c) an intracellular signaling domain; and
(d) optionally, one or more co-stimulatory domains.

### Claim 62 (depends on 61)

The composition of claim 61, wherein the extracellular target moiety is a scFv derived from an antibody that specifically recognizes a CD19 target molecule.

### Claim 63 (depends on 61)

The composition of claim 61, wherein the immunotherapeutic agent is a cytokine selected from the group consisting of IL2, IL12 and IL15.

### Claim 64 (depends on 61)

The composition of claim 61, wherein the immunotherapeutic agent is a cytokine-cytokine receptor fusion polypeptide that comprises the whole or a portion of IL15, fused to the whole or a portion of IL15Ra to produce a IL15-IL15Ra fusion polypeptide.

### Claim 65 (depends on 52)

The composition of claim 52, wherein the SRE is responsive to one or more stimuli, and wherein said one or more stimuli is selected from Tadalafil, Vardenafil, Sildenafil, Avanafil, Lodenafil, Mirodenafil, Udenafil, Benzamidenafil, Dasantafil, and Beminafil.

### Claim 66 (depends on 52)

A pharmaceutical composition comprising the composition of claim 52 and a pharmaceutically acceptable excipient.

### Claim 67 (depends on 52)

A polynucleotide encoding the composition of claim 52.

### Claim 68 (depends on 67)

A pharmaceutical composition comprising the polynucleotide of claim 67 and a pharmaceutically acceptable excipient.

### Claim 69 (depends on 67)

A vector comprising the polynucleotide of claim 67.

### Claim 70 (depends on 67)

A cell comprising the polynucleotide of claim 67.

### Claim 71 (depends on 70)

The cell of claim 70, wherein said cell is an immune cell for adoptive cell transfer (ACT), and optionally wherein the immune cell is a CD8+ T cell, a CD4+ T cell, a memory T cell, a terminally differentiated effector T cell, a natural killer (NK) cell, a NK T cell, a tumor infiltrating lymphocyte (TIL), a cytotoxic T lymphocyte (CTL), a regulatory T cell (Treg), or a dendritic cell (DC).

### Claim 72 (depends on 70)

A pharmaceutical composition comprising the cell of claim 70 and a pharmaceutically acceptable excipient.

### Claim 73 (depends on 67)

A method of producing a modified cell, said method comprising introducing into a cell a nucleic acid molecule comprising the polynucleotide of claim 67.

### Claim 74 (depends on 70)

A method of modulating expression, function, and/or level of a payload in the cell of claim 70, said method comprising:
administering to the cell a stimulus,
wherein the SRE is responsive to the stimulus and wherein the expression, function, and/or level of the payload is modulated in response to the stimulus.

### Claim 75 (depends on 71)

A method of inducing an immune response in the immune cell of claim 71, wherein the payload is an immunotherapeutic agent, said method comprising:
administering to the cell a therapeutically effective amount of a stimulus to modulate the expression of the immunotherapeutic agent, wherein the immunotherapeutic agent is capable of inducing an immune response in the cell in response to the stimulus.

### Claim 76 (depends on 71)

A method of reducing a tumor burden in a subject, comprising:
(a) administering to the subject a therapeutically effective amount of the immune cells of claim 71; and
(b) administering to the subject a therapeutically effective amount of a stimulus, wherein the stimulus is a ligand, to modulate the expression of the immunotherapeutic agent, thereby reducing the tumor burden.

### Claim 77 (depends on 70)

A method of treating a disease in a subject in need thereof, said method comprising:
(a) administering to the subject a therapeutically effective amount of the cell of claim 70,
wherein the cell comprises a payload that treats the disease; and
(b) administering to the subject a therapeutically effective amount of a stimulus,
wherein the SRE is responsive to the stimulus and wherein expression of the payload is modulated in response to the stimulus to thereby treat the disease.
